Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone.

Authors: Hargrove JT, Maxson WS, Wentz AC, Burnett LS.

Publication Year: 1989

Citation: Obstet Gynecol 1989; 73( 4):606-12.

Fifteen menopausal subjects were studied to determine the efficacy and safety of hormone replacement therapy with micronized estradiol (E2) and progesterone. Ten subjects were given 0.7-E2 (1.05 mg daily) and progesterone (200-300 mg daily) and evaluated over one year at month 0, 1, 3, 6 and 12. Five subjects were administered conjugated estrogens (0.625mg daily) and medroxyprogesterone acetate (10 mg daily) and evaluated at the same intervals. Results showed all 10 women on E2 and progesterone had a decrease in total cholesterol with an increase in HDLs and sustained amenorrhea with no endometrial hyperplasia or withdrawal bleeding after six months of observation. Four of five women in the conjugated estrogen group continued to have withdrawal bleeding without endometrial hyperplasia. HDLs also increased in this group but no significant change in total cholesterol was found.